1 study found for:    CAMN107AUS28
Show Display Options
Rank Status Study
1 Recruiting CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
Condition: Chronic Myelogenous Leukemia in Chronic Phase
Intervention: Drug: nilotinib

Indicates status has not been verified in more than two years